Last reviewed · How we verify
NCT07121244
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
Phase 1 trial testing 68Ga-R11228 in Locoregionally Recurrent Hormone-receptor Positive Breast Cancer in 62 participants. Currently enrolling.
1 June 2028
Quick facts
| Lead sponsor | Radionetics Oncology |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 1 October 2025 |
| Primary completion | 1 June 2028 |
| Estimated completion | 1 June 2033 |
| Sites | 7 locations across United States, Australia |
Drugs / interventions tested
- 68Ga-R11228 — full drug profile →
- 177Lu-R11228 — full drug profile →
Conditions studied
- Locoregionally Recurrent Hormone-receptor Positive Breast Cancer — all drugs for Locoregionally Recurrent Hormone-receptor Positive Breast Cancer →
- Metastatic Hormone Receptor Positive Breast Cancer — all drugs for Metastatic Hormone Receptor Positive Breast Cancer →
Sponsor
Radionetics Oncology — full company profile →
Who can join
18 and older, any sex, with Locoregionally Recurrent Hormone-receptor Positive Breast Cancer or Metastatic Hormone Receptor Positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07121244
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Radionetics Oncology trials
Trials by the same sponsor.
- NCT05999292 — Phase 1 Study of 68Ga-R8760 · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07121244 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radionetics Oncology
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07121244.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing